Lucio Crinò

45.0k total citations · 10 hit papers
372 papers, 19.4k citations indexed

About

Lucio Crinò is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Lucio Crinò has authored 372 papers receiving a total of 19.4k indexed citations (citations by other indexed papers that have themselves been cited), including 284 papers in Pulmonary and Respiratory Medicine, 262 papers in Oncology and 93 papers in Molecular Biology. Recurrent topics in Lucio Crinò's work include Lung Cancer Treatments and Mutations (252 papers), Lung Cancer Research Studies (125 papers) and Colorectal Cancer Treatments and Studies (67 papers). Lucio Crinò is often cited by papers focused on Lung Cancer Treatments and Mutations (252 papers), Lung Cancer Research Studies (125 papers) and Colorectal Cancer Treatments and Studies (67 papers). Lucio Crinò collaborates with scholars based in Italy, United States and France. Lucio Crinò's co-authors include Federico Cappuzzo, Enriqueta Felip, Vienna Ludovini, Giulio Metro, Maurizio Tonato, Giorgio V. Scagliotti, Filippo de Marinis, Stefania Bartolini, Alice T. Shaw and Pasi A. Jänne and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Lucio Crinò

369 papers receiving 19.0k citations

Hit Papers

Phase III Trial of Infusi... 2002 2026 2010 2018 2007 2012 2002 2012 2016 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
    2007 872 citations Lucio Crinò et al. Journal of Clinical Oncology profile →
  2. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
    2012 776 citations Lucio Crinò et al. The Lancet Oncology profile →
  3. Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
    2002 739 citations Giorgio V. Scagliotti, Filippo de Marinis et al. Journal of Clinical Oncology profile →
  4. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
    2012 512 citations Pasi A. Jänne, Alice T. Shaw et al. The Lancet Oncology profile →
  5. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
    2016 502 citations Chun‐Ming Tsai, Lucio Crinò et al. The Lancet Oncology profile →
  6. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
    2014 492 citations Armida D’Incecco, Mariacarla Andreozzi et al. British Journal of Cancer profile →
  7. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
    2015 468 citations Alice T. Shaw, Myung‐Ju Ahn et al. Journal of Clinical Oncology profile →
  8. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2013 458 citations Martin Früh, Dirk De Ruysscher et al. Annals of Oncology profile →
  9. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2010 424 citations Lucio Crinò, Enriqueta Felip et al. Annals of Oncology profile →
  10. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
    2017 412 citations Alice T. Shaw, Tae Min Kim et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lucio Crinò Italy 67 13.5k 13.4k 5.5k 3.3k 1.3k 372 19.4k
Alan Sandler United States 44 17.9k 1.3× 15.6k 1.2× 5.9k 1.1× 3.3k 1.0× 1.2k 0.9× 163 23.8k
Sai‐Hong Ignatius Ou United States 65 11.8k 0.9× 14.1k 1.1× 5.6k 1.0× 3.5k 1.1× 1.2k 0.9× 349 17.6k
Lesley Seymour Canada 61 13.8k 1.0× 13.6k 1.0× 5.3k 1.0× 3.8k 1.2× 1.8k 1.4× 258 22.2k
D. Ross Camidge United States 77 15.0k 1.1× 16.9k 1.3× 8.6k 1.6× 4.6k 1.4× 1.4k 1.1× 539 24.2k
Tudor–Eliade Ciuleanu Romania 47 12.7k 0.9× 11.7k 0.9× 3.9k 0.7× 2.7k 0.8× 1.3k 1.0× 202 17.3k
Igor Bondarenko United States 54 13.3k 1.0× 9.0k 0.7× 3.3k 0.6× 3.6k 1.1× 1.2k 1.0× 317 17.7k
Mark A. Socinski United States 69 15.1k 1.1× 14.6k 1.1× 4.9k 0.9× 3.0k 0.9× 1.2k 1.0× 518 22.3k
Federico Cappuzzo Italy 63 16.9k 1.3× 16.9k 1.3× 7.0k 1.3× 4.3k 1.3× 1.5k 1.2× 360 24.6k
Joachim von Pawel Germany 64 17.7k 1.3× 16.9k 1.3× 7.2k 1.3× 3.2k 1.0× 1.3k 1.0× 254 25.0k
Benjamin Solomon Australia 61 12.7k 0.9× 14.1k 1.1× 6.7k 1.2× 4.3k 1.3× 1.5k 1.2× 415 20.8k

Countries citing papers authored by Lucio Crinò

Since Specialization
Citations

This map shows the geographic impact of Lucio Crinò's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lucio Crinò with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lucio Crinò more than expected).

Fields of papers citing papers by Lucio Crinò

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lucio Crinò. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lucio Crinò. The network helps show where Lucio Crinò may publish in the future.

Co-authorship network of co-authors of Lucio Crinò

This figure shows the co-authorship network connecting the top 25 collaborators of Lucio Crinò. A scholar is included among the top collaborators of Lucio Crinò based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lucio Crinò. Lucio Crinò is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maltoni, Roberta, Claudio Cerchione, Sara Bravaccini, et al.. (2025). Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy. Frontiers in Immunology. 16. 1515748–1515748. 6 indexed citations
2.
Rocca, Andrea, Lucio Crinò, Luca Braga, et al.. (2025). Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies. British Journal of Cancer. 133(10). 1405–1427.
3.
Verlicchi, Alberto, Matteo Canale, Elisa Chiadini, et al.. (2023). The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer. Life. 13(9). 1915–1915. 1 indexed citations
4.
Massa, Ilaria, Flavia Foca, Angelo Delmonte, et al.. (2022). Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. Cancers. 14(18). 4481–4481. 4 indexed citations
5.
Shaw, Alice T., Tae Min Kim, Lucio Crinò, et al.. (2017). Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology. 18(7). 874–886. 412 indexed citations breakdown →
6.
Castro, Gilberto de, Daniel Shao-Weng Tan, Lucio Crinò, et al.. (2017). PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4). Journal of Thoracic Oncology. 12(1). S7–S7. 8 indexed citations
7.
Gridelli, Cesare, Paul Baas, Fabrice Barlési, et al.. (2017). Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer. 19(4). 301–314. 8 indexed citations
8.
9.
Canale, Matteo, Elisabetta Petracci, Angelo Delmonte, et al.. (2016). Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. Clinical Cancer Research. 23(9). 2195–2202. 196 indexed citations
10.
Ricciuti, Biagio, Giulia C. Leonardi, Giulio Metro, et al.. (2015). Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Review of Respiratory Medicine. 10(1). 53–68. 52 indexed citations
11.
D’Incecco, Armida, Mariacarla Andreozzi, Vienna Ludovini, et al.. (2014). PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. British Journal of Cancer. 112(1). 95–102. 492 indexed citations breakdown →
12.
Bennati, Chiara, Dara L. Aisner, Rita Chiari, et al.. (2013). Identification of Targetable Driver Mutations In Molecularly Selected Never Smoker Lung Adenocarcinomas. Journal of Thoracic Oncology. 8. 1 indexed citations
13.
Marchetti, Antonio, Andrea Ardizzoni, Mauro Papotti, et al.. (2013). Recommendations for the Analysis of ALK Gene Rearrangements in Non–Small-Cell Lung Cancer: A Consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. Journal of Thoracic Oncology. 8(3). 352–358. 40 indexed citations
14.
Früh, Martin, Dirk De Ruysscher, Sanjay Popat, et al.. (2013). Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 24. vi99–vi105. 458 indexed citations breakdown →
15.
16.
Metro, Giulio, Jennifer Foglietta, Michelangelo Russillo, et al.. (2010). Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Annals of Oncology. 22(3). 625–630. 120 indexed citations
17.
18.
19.
Gregorc, Vanesa, Giovanni Luca Ceresoli, Irene Floriani, et al.. (2004). Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research. 10(18). 6006–6012. 37 indexed citations
20.
Crinò, Lucio, Enrico Franceschi, & L. Scopece. (2002). HER-2 Inhibitors: Clinical Results. Tumori Journal. 1(6_suppl1). S3–S4. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alan Sandler Breakdown of academic impact, for papers by Sai‐Hong Ignatius Ou Breakdown of academic impact, for papers by Lesley Seymour Breakdown of academic impact, for papers by D. Ross Camidge Breakdown of academic impact, for papers by Tudor–Eliade Ciuleanu Breakdown of academic impact, for papers by Igor Bondarenko Breakdown of academic impact, for papers by Mark A. Socinski Breakdown of academic impact, for papers by Federico Cappuzzo Breakdown of academic impact, for papers by Joachim von Pawel Breakdown of academic impact, for papers by Benjamin Solomon
Rankless by CCL
2026